US Health Authorities Turn To Israeli Universal Flu Vaccine Maker To Ward Off Next Influenza Outbreak
The National Institutes of Health announced a new Phase 2 clinical trial of the M-001 vaccine candidate, developed and produced by BiondVax Pharmaceuticals.
May 08, 2018
Israel’s BiondVax Moves Closer To Universal Flu Vaccine
Deal will help Biondvax bring M-001, designed to protect against all current and future flu strains, closer to market.
June 27, 2017
